These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 21339489)

  • 21. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720.
    Kihara A; Igarashi Y
    Biochim Biophys Acta; 2008 Sep; 1781(9):496-502. PubMed ID: 18555808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sphingosine 1-phosphate in coagulation and inflammation.
    Obinata H; Hla T
    Semin Immunopathol; 2012 Jan; 34(1):73-91. PubMed ID: 21805322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
    Camm J; Hla T; Bakshi R; Brinkmann V
    Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
    Kipp M; Amor S
    Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fingolimod modulates microglial activation to augment markers of remyelination.
    Jackson SJ; Giovannoni G; Baker D
    J Neuroinflammation; 2011 Jul; 8():76. PubMed ID: 21729281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individual variation of human S1P₁ coding sequence leads to heterogeneity in receptor function and drug interactions.
    Obinata H; Gutkind S; Stitham J; Okuno T; Yokomizo T; Hwa J; Hla T
    J Lipid Res; 2014 Dec; 55(12):2665-75. PubMed ID: 25293589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
    Tian YL; Jin J; Wang XJ
    Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The sphingosine 1-phosphate transporter, SPNS2, functions as a transporter of the phosphorylated form of the immunomodulating agent FTY720.
    Hisano Y; Kobayashi N; Kawahara A; Yamaguchi A; Nishi T
    J Biol Chem; 2011 Jan; 286(3):1758-66. PubMed ID: 21084291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
    Brinkmann V
    Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.
    Cyster JG; Schwab SR
    Annu Rev Immunol; 2012; 30():69-94. PubMed ID: 22149932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles for lysophospholipid S1P receptors in multiple sclerosis.
    Noguchi K; Chun J
    Crit Rev Biochem Mol Biol; 2011 Feb; 46(1):2-10. PubMed ID: 20979571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular targets of FTY720 (fingolimod).
    Pitman MR; Woodcock JM; Lopez AF; Pitson SM
    Curr Mol Med; 2012 Dec; 12(10):1207-19. PubMed ID: 22834825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
    Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
    Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
    Takabe K; Paugh SW; Milstien S; Spiegel S
    Pharmacol Rev; 2008 Jun; 60(2):181-95. PubMed ID: 18552276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional characterization of sphingosine 1-phosphate receptor agonist in human endothelial cells.
    Butler J; Lana D; Round O; LaMontagne K
    Prostaglandins Other Lipid Mediat; 2004 Jan; 73(1-2):29-45. PubMed ID: 15165029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central effects of fingolimod.
    Cruz VT; Fonseca J
    Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sphingosine 1-phosphate chemical biology.
    Lynch KR; Macdonald TL
    Biochim Biophys Acta; 2008 Sep; 1781(9):508-12. PubMed ID: 18638568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.